---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-000411"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:42:23.587727+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference

## Summary
- Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.
- Forward-looking statements reference expected cash runway into mid-2026 and potential to grow ZYNLONTA revenue.
- Presentation highlights pipeline including LOTIS 5, LOTIS 7, ADCT-602, and exatecan-based solid tumor platform.
- ZYNLONTA is approved for relapsed/refractory large B-cell lymphoma after two prior therapies.

## SEC filing metadata
- accession: 0000950103-25-000411
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010325000411/0000950103-25-000411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010325000411/dp223356_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-000411
- JSON: https://secwatch.observer/filing/0000950103-25-000411.json
- Plain text: https://secwatch.observer/filing/0000950103-25-000411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.